193. Prader-Willi syndrome Clinical trials / Disease details

Clinical trials : 111 / Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02810483 (ClinicalTrials.gov)	December 2012	17/5/2016	Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks	Randomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 Weeks	Prader-Willi Syndrome	Drug: Topiramate;Drug: Placebo Comparator	Assistance Publique - Hôpitaux de Paris	NULL	Terminated	12 Years	45 Years	All	69	Phase 3	France
2	NCT00065923 (ClinicalTrials.gov)	July 2002	1/8/2003	Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome	Topiramate Effects on SIB in Prader-Willi Syndrome	Prader-Willi Syndrome;Self-Injurious Behavior	Drug: Topiramate	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	18 Years	66 Years	Both	10	N/A	United States
3	EUCTR2011-003432-32-FR (EUCTR)		13/10/2011	N/A	N/A - TOPRADER	MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]	Trade Name: Topiramate Product Name: Topiramate INN or Proposed INN: topiramate	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	125	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France